{"id":"sun-131-1-5-tds","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Eye irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SUN-131 1.5% TDS works by inhibiting bacterial growth and reducing inflammation in the conjunctiva. It is effective against a wide range of bacteria, including Staphylococcus aureus and Streptococcus pneumoniae.","oneSentence":"SUN-131 1.5% TDS is a topical sulfonamide antibiotic used to treat bacterial conjunctivitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:45.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"}]},"trialDetails":[{"nctId":"NCT03248440","phase":"PHASE3","title":"Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion","status":"COMPLETED","sponsor":"Senju USA, Inc.","startDate":"2017-07-31","conditions":"Chalazion","enrollment":263},{"nctId":"NCT02338648","phase":"PHASE2","title":"Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion","status":"COMPLETED","sponsor":"Senju USA, Inc.","startDate":"2014-10","conditions":"Chalazion","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":167,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SUN-131 1.5% TDS","genericName":"SUN-131 1.5% TDS","companyName":"Senju USA, Inc.","companyId":"senju-usa-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SUN-131 1.5% TDS is a small molecule transdermal system being studied for its safety and efficacy in treating chalazion. It is being compared to a placebo transdermal system in a randomized, double-masked clinical trial (NCT03248440).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}